ivWatch Reports Record Technology Adoption and Expansion in 2023

The IV Safety Company Makes Major Inroads in U.K., Italy, Netherlands, and U.S.

Newport News, VA, January 17, 2024 – In its 13th year, ivWatch, LLC, the IV safety company, closed out 2023 with a record number of milestones as it pursued its ongoing mission to improve and promote IV safety around the globe, laying a strong foundation for expansion in 2024. The company successfully surpassed over 7.7 million hours of patient monitoring, the technology has been used on more than 230,000 patients worldwide, and three of the top ten children’s hospitals in the US have adopted the innovation. ivWatch has successfully passed 11 audits with no major findings, is sold in more than ten countries, and all 100,000 shipments were precisely manufactured in Virginia, USA with pristine quality assurance on every order.

The company’s 2023 milestones include:

Filings

The company surpassed its 69th patent award for its proprietary biosensor technology, which connects to a patient monitor that notifies clinicians to take action if fluid is leaking outside of a patient’s vein. The sophisticated technology uses near infrared and visible light combined with a predictive algorithm for high sensitivity and specificity.

The announcement of its filing for 510(k) clearance from the U.S. Food and Drug Administration (FDA) to detect extravasation events via its biosensor technology during iron infusions. 

Clinical Studies Published

A study published in The Journal of Vascular Access (JVA) examining several important metrics that describe the performance of the ivWatch patient monitoring system for infiltrations and extravasations in a 24-bed neonatal intensive care unit (NICU) at Wilhelmina Children’s Hospital, part of the University Medical Centre of Utrecht in the Netherlands. The study found that continuous infusion site monitoring using the ivWatch system detects PIVIE events earlier rather than relying on intermittent visual observation alone, and that detection occurred in 100% of leakage events prior to a clinician detecting such an event.

A second study conducted by Gemelli University Polyclinic in Rome and also published in JVA examined the ivWatch patient monitoring system’s early detection of infiltrations and extravasations in a 16-bed NICU. The study found an overall sensitivity of 88.9% in detecting infiltration before the clinician, where the clinician is considered the gold standard. On average, infiltration events were detected six hours prior to a clinical diagnosis. 

Global Reach

Clearance to sell in a wide range of new geographies, including the United Kingdom, Ireland, and New Zealand were added to the roster of countries already fully established including the United States, Canada, Europe, Qatar, United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, and Australia.

Attendance at multiple conferences around the world, including MEDICA (Germany); American Organization for Nursing Leadership (AONL), American Association of Critical Care Nurses, Association for Vascular Access (AVA), and American Nurses Credentialing Center’s (ANCC) National Magnet & Pathway to Excellence Conferences (U.S.); NIVAS, IV Summit 23, and IV Therapy Summit (U.K.). 

Awards:

Winning a PM360 Innovation Award in “Health Tech Non-Consumer” category

ivWatch’s COO Jaclyn Lautz, Ph.D. honored with a 2023 Women in Business Award from Inside Business

Finalist for a 2023 Fierce Life Sciences Innovation Award

​​Presented with two Muse Creative and Design awards for the Marketing & Promotional – Brochure category including a Gold award in the competition alongside Branded Content – B2B, Silver award. 

New Partnerships:

Three new international distributors were signed: Healthcare 21 Group (UK/Ireland), Medlands Medical (Qatar), and USL Medical (New Zealand). 

A sole source group purchasing agreement was awarded with Premier, Inc. through its KIINDO pediatric performance group and collaborative. The new multi-year agreement provides top children’s hospitals access to groundbreaking ivWatch technology and allows for a seamless transition to innovative products which help keep even the tiniest patients safer.

A new United States distribution partnership aligned ivWatch with Marathon Medical Corp., a leader in healthcare distribution and service-disabled veteran-owned small business (SDVOSB). With a focus on providing top notch customer service to both VA/DOD facilities and those who chose to serve our country.

We proudly joined the National Patient Safety Board Advocacy Coalition which is a team of leading healthcare organizations and thought leaders calling for the installation of a National Patient Safety Board. The NPSB proclaims that it “would guarantee a data-driven, scalable approach to preventing and reducing patient safety events in healthcare settings.”

A partnership with Patients for Safer Nuclear Medicine, a coalition of patient advocacy organizations and corporate partners who are dedicated to ensuring safer nuclear medicine procedures.

Joined together with Patients for Patient Safety, a network of people and organizations aligned with the World Health Organization and focused on making healthcare safe in the United States.

The ivWatch continuous IV site monitoring system consists of a disposable miniaturized sensor that is connected to a patient monitor that notifies clinicians if fluid is leaking outside of their patient’s vein. Due to the potential severity of infiltrations, it is critical for clinicians to identify these adverse events as soon as possible to prevent patient injury.

For more information on how the technology works, visit: https://www.ivwatch.com/tech-overview/.

About ivWatch, LLC

ivWatch, LLC  is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative IV monitoring solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch, Facebook@ivWatchLLC, Instagram @ivWatchLLC and LinkedIn @ivWatch-LLC, or visit www.ivWatch.com.

Meet us at NICA | June 21st - June 22nd | **BOOK TODAY**
Meet us at NICA | June 21st - June 22nd | **BOOK TODAY**